What is it about?
A recent analysis of R&D productivity suggests that there are grounds for ‘cautious optimism’ that the industry ‘turned the corner’ in 2008 and is ‘on the comeback trail’. We believe that this analysis is flawed and most probably wrong.
Featured Image
Why is it important?
Reducing minimum time to market increased overall development costs considerably. We show that deciding when and how to kill candidate projects requires more thought and rigour.
Read the Original
This page is a summary of: R&D productivity rides again?, Pharmaceutical Statistics, October 2014, Wiley,
DOI: 10.1002/pst.1653.
You can read the full text:
Resources
Some statistical issues in project prioritization in the pharmaceutical industry
Various aspects of portfolio management and project prioritization within the pharmaceutical industry are examined. It is shown that the cost and probability architecture of a project is a crucial aspect of its value. An appropriate simple tool for ranking projects is the Pearson index. Various difficulties are considered.
Further Statistical Issues in Project Prioritization in the Pharmaceutical Industry
Various aspects of portfolio management within the pharmaceutical industry are considered. It is shown that some popular notions of risk management are incorrect. Some additional practical matters are also touched upon.
Contributors
The following have contributed to this page
